Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01791894 · ClinicalTrials.gov registry record · Phase 1
Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma
A Phase 1 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT01791894: Completed Phase 1 study, sponsored by Stanford University.
NCT01791894 is a Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 5 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01791894, a Phase 1 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This pilot clinical trial studies arsenic trioxide in treating patients with basal cell carcinoma. Drugs used in chemotherapy, such as arsenic trioxide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stop them from dividing
Interventions
- DRUG arsenic trioxide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2013-04 |
| Est. Completion | 2015-11 |
| Phase | Phase 1 |
What the finished NCT01791894 record still lists
NCT01791894 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 1 intervention - of which arsenic trioxide is the first listed.
NCT01791894 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01791894 about?
NCT01791894 is a clinical study titled "Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma". This pilot clinical trial studies arsenic trioxide in treating patients with basal cell carcinoma. Drugs used in chemotherapy, such as arsenic trioxide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stop them from dividing
What is the current status of trial NCT01791894?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2013-04. Estimated completion is 2015-11.
What interventions are being tested in trial NCT01791894?
The interventions under investigation include: arsenic trioxide (DRUG).
Who is sponsoring clinical trial NCT01791894?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01791894's enrollment target sits among peer trials
5 1989th of 2000 higher than 6 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia